The Product: Gluco Plus
 Regulatory Status: National Drug Authority (NDA) notified & shelf-stable.  IP Protection: Proprietary, trade-secret formulation secured. 
 Scientific Validation:
 1. Preclinical toxicity & efficacy studies successfully completed.
 2. Clinical protocol for randomized controlled trial (RCT) finalized – Phase 1/2 ready. 
 Formulation Strength: Natural, safe, effective, and positioned for both preventive and
therapeutic diabetes management. 

Market Opportunity
 Global Diabetes Care Market: US$ 132 billion. 
 Natural Antidiabetic Segment: Growing at 9% CAGR, driven by consumer preference for
plant-based, side-effect-free solutions.
 Regulatory Edge: NDA status enables regulated label claims, accelerating adoption in
pharmacy chains, hospitals, and direct-to-consumer (DTC) platforms. 
 Regional Advantage: Uganda-based manufacturing provides a cost-efficient, scalable
production hub for local, regional, and international markets. 

Competitive Advantages
 IP-Ready, Scientifically Validated Formula with proven consumer demand. 
 High-margin business model across B2C (retail, e-commerce) and B2B (pharmacies, hospitals, licensing deals). 
 Strong buyout potential for larger nutraceutical, pharmaceutical, or wellness companies. 

Value Creation & Exit Potential
 Direct Brand Acquisition – Scale Gluco Plus and pipeline products for strategic exit. 
 White-Label Licensing – Partner with pharmaceutical & nutraceutical firms globally. 
 Co-Branding & Royalty-Based Partnerships – Long-term recurring revenue streams. 

ESG & Impact Value
 Sustainable Sourcing: Employing African farmers through contract farming of medicinal
herbs. 
 Cultural Preservation: Promoting traditional African medicinal knowledge through science- backed validation. 
 Community Empowerment: Building an export-ready nutraceutical industry that
strengthens rural livelihoods.

Use of Funds (US$ 3 million)
Clinical Trials (Phase 1/2 & Phase 3): $1.2M
Manufacturing Scale-Up (GMP-compliant facility): $0.9M
Market Launch & Commercialization: $0.6M
Working Capital & Regulatory Expansion: $0.3M

Financial Highlights
Investment Ask: US$ 3 million for 20% equity. 
Implied Valuation: US$ 15 million pre-money. 
Projected Revenues:
	Year 3: US$ 10M (domestic + regional market penetration). 
	Year 5: US$ 45M (global distribution + licensing deals). 
Gross Margins: >65% expected. Exit Multiple Potential: 5–10x within 5–7 years. 

Why Invest Now?
 Phase 1/2 Clinical Trial Ready – key inflection point in product validation. 
 Favorable Market Timing – rising diabetes prevalence and consumer demand for natural
remedies. 
 Regulatory First-Mover Advantage in Africa for evidence-based nutraceuticals. 
 Impact Investment Alignment – health equity, African innovation, sustainable agriculture. 

Gluco Plus represents a unique convergence of science, tradition, and market opportunity. With
a validated formula, clear regulatory pathway, and scalable production in Uganda, we are poised
to capture a significant share of the fast-growing natural diabetes care segment globally. 

We invite strategic investors to join us in scaling this innovation — US$ 3 million for 20% equity — and help us transform diabetes care while driving sustainable impact across Africa and beyond.